Top Industry Leaders in the Biopharmaceuticals Market
Latest Biopharmaceuticals Companies Update
Bristol Myers Squibb Acquires Turning Point Therapeutics: This USD 3.4 billion deal bolsters Bristol Myers Squibb's oncology pipeline with Turning Point's TP-5992, a promising drug candidate for solid tumors.
AbbVie Snaps Up Teneobio: This USD 1.6 billion acquisition strengthens AbbVie's immunology portfolio with Teneobio's TNX-102, a potential treatment for inflammatory bowel disease.
Regeneron Receives FDA Approval for Dupixent to Treat Eosinophilic Esophagitis: This expands the reach of Dupixent, a blockbuster drug already approved for asthma, eczema, and other allergic conditions.
AstraZeneca's Imfinzi Wins FDA Approval for Extensive-Stage Small Cell Lung Cancer: This marks a significant milestone in the treatment of this aggressive cancer, offering a new option for patients.
List of Biopharmaceuticals Key companies in the market
- Pfizer, Inc. (US)
- Amgen Inc. (US)
- Eli Lilly and Company (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Johnson & Johnson (US)
- Gilead Sciences, Inc. (US)
- AstraZeneca (UK)
- Abbvie Inc. (US)
- Sanofi (France)
- Bristol-Myers Squibb Company (US)
- Sandoz International GmbH (Germany)
- Novo Nordisk A/S (Denmark)
- GlaxoSmithKline PLC (UK)
- Merck KGaA (Germany)
- Biocon (India)
